Investor Relations

Contact Us

KiteKonnect®

Press Releases

Filter By Year

2020

June 12, 2020
Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe

May 29, 2020
Yescarta® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
May 13, 2020
Gilead and Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting

April 30, 2020
Gilead Sciences Announces First Quarter 2020 Financial Results
April 21, 2020
Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells
April 02, 2020
Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma

February 10, 2020
U.S. FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma

January 28, 2020
European Medicines Agency Validates Kite’s Marketing Application for Company’s Second CAR T Cell Therapy

Filter By Year